The effect of daily consumption of probiotic yogurt on albumin to creatinine Ratio, eGFR and metabolic parameters in type 2 diabetic patients with microalbuminuria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201125049491N1

Enrollment

Registered

2020-12-28

Start date

2021-11-11

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy

Interventions

Intervention 1: Intervention group: They will receive 300g of probiotic yogurt(Haraz Company) enriched with Bifidobacterium lactis and Lactobacillus acidophilus strains daily for 8 weeks. Microbiologi

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Diabetic nephropathy with microalbuminuria (Albumin to creatinine ratio 30-299 mg / g Cr, eGFR= 30 ml / min / 1.73m2) Has an age of 80-20 years BMI less than 40 kg / m2

Exclusion criteria

Exclusion criteria: History of chronic diseases including: IBD, liver disease, rheumatoid arthritis, renal disorders except diabetic nephropathy Smoking, alcohol and tobacco History of taking antibiotics and NSAIDS (during the last month) Take omega 3 supplements and vitamins E and C during the last three months Consumption of probiotic supplements or foods containing probiotics during the last three months Lactose intolerance Pregnancy

Design outcomes

Primary

Measure	Time frame
Albumin to creatinine ratio. Timepoint: First the intervention and 8 weeks later at the end of the intervention. Method of measurement: Laboratory kits.	—

Secondary

Measure	Time frame
EGFR. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;TG. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;TC. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;LDL. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;HDL. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;FBS. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;HbA1c. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;Hs-CRP. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.	—

Measure

Time frame

EGFR. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;TG. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;TC. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;LDL. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;HDL. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;FBS. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;HbA1c. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.;Hs-CRP. Timepoint: At the beginning of the intervention and 8 weeks later at the end of the intervention. Method of measurement: Special laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mojtaba Ghoreishy

Tehran University of Medical Sciences

seyed.mojtaba.ghoreishy@gmail.com+98 86 4222 8244

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026